Shionogi & Co. Ltd. and Pfizer Inc. have signed agreements with the National Health Service in England that will delink the payments they receive for their respective antibiotics Fetcroja (cefiderocol) and Zavicefta (ceftazidime–avibactam) from the volume of the drugs sold. The innovative subscription model that underlies the agreements is a world first and could provide a solution to stimulating more innovation in the field of developing new antibiotic and help tackle the problem of antimicrobial resistance (AMR).
In separate news, Shionogi has also signed two other agreements that will expand access to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?